GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sera Prognostics Inc (NAS:SERA) » Definitions » Beneish M-Score

SERA (Sera Prognostics) Beneish M-Score : -4.08 (As of Dec. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.08 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sera Prognostics's Beneish M-Score or its related term are showing as below:

SERA' s Beneish M-Score Range Over the Past 10 Years
Min: -4.08   Med: -1.16   Max: 453.85
Current: -4.08

During the past 5 years, the highest Beneish M-Score of Sera Prognostics was 453.85. The lowest was -4.08. And the median was -1.16.


Sera Prognostics Beneish M-Score Historical Data

The historical data trend for Sera Prognostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics Beneish M-Score Chart

Sera Prognostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - 453.85 -1.19 -2.32

Sera Prognostics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.30 -2.32 -3.26 4.75 -4.08

Competitive Comparison of Sera Prognostics's Beneish M-Score

For the Medical Devices subindustry, Sera Prognostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sera Prognostics's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's Beneish M-Score falls into.



Sera Prognostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sera Prognostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.7893+0.528 * 1.2106+0.404 * 0.7269+0.892 * 0.2848+0.115 * 1.0452
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.7118+4.679 * -0.237364-0.327 * 1.8952
=-4.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $0.08 Mil.
Revenue was 0.029 + 0.024 + 0 + 0.041 = $0.09 Mil.
Gross Profit was 0.016 + 0.004 + -0.017 + 0.017 = $0.02 Mil.
Total Current Assets was $51.11 Mil.
Total Assets was $79.00 Mil.
Property, Plant and Equipment(Net PPE) was $2.19 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.83 Mil.
Selling, General, & Admin. Expense(SGA) was $20.59 Mil.
Total Current Liabilities was $24.18 Mil.
Long-Term Debt & Capital Lease Obligation was $0.17 Mil.
Net Income was -7.919 + -8.303 + -8.097 + -7.925 = $-32.24 Mil.
Non Operating Income was 0.215 + 0.287 + 0.339 + 0.361 = $1.20 Mil.
Cash Flow from Operations was -6.995 + -5.928 + 4.994 + -6.765 = $-14.69 Mil.
Total Receivables was $0.16 Mil.
Revenue was 0.042 + 0.123 + 0.1 + 0.065 = $0.33 Mil.
Gross Profit was -0.002 + 0.043 + 0.038 + 0.006 = $0.09 Mil.
Total Current Assets was $47.55 Mil.
Total Assets was $90.06 Mil.
Property, Plant and Equipment(Net PPE) was $2.20 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.89 Mil.
Selling, General, & Admin. Expense(SGA) was $26.66 Mil.
Total Current Liabilities was $13.55 Mil.
Long-Term Debt & Capital Lease Obligation was $1.10 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.079 / 0.094) / (0.155 / 0.33)
=0.840426 / 0.469697
=1.7893

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.085 / 0.33) / (0.02 / 0.094)
=0.257576 / 0.212766
=1.2106

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (51.107 + 2.187) / 79.001) / (1 - (47.546 + 2.197) / 90.057)
=0.325401 / 0.44765
=0.7269

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.094 / 0.33
=0.2848

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.891 / (0.891 + 2.197)) / (0.834 / (0.834 + 2.187))
=0.288536 / 0.276068
=1.0452

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(20.594 / 0.094) / (26.661 / 0.33)
=219.085106 / 80.790909
=2.7118

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.168 + 24.182) / 79.001) / ((1.101 + 13.545) / 90.057)
=0.308224 / 0.16263
=1.8952

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-32.244 - 1.202 - -14.694) / 79.001
=-0.237364

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sera Prognostics has a M-score of -4.08 suggests that the company is unlikely to be a manipulator.


Sera Prognostics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sera Prognostics Business Description

Traded in Other Exchanges
N/A
Address
2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
Executives
Austin Aerts officer: Chief Financial Officer 2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
John J. Boniface officer: Chief Scientific Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Paul Kearney officer: Chief Data Officer 2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Mansoor Raza Mirza director C/O KARYOPHARM THERAPEUTICS INC., 2 MERCER ROAD, NATICK MA 01760
Benjamin Jackson officer: General Counsel 320 WAKARA WAY, SALT LAKE CITY UT 84108
Robert Gardner Harrison officer: Chief Information Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Zhenya Lindgardt director C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley officer: Chief Medical Officer C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence director C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Gregory C Critchfield director, officer: Chief Executive Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jay M Moyes officer: Chief Financial Officer
Blue Ox Healthcare Partners Sp, Llc 10 percent owner 135 E. 57TH STREET, 23RD FLOOR, NEW YORK NY 10022
Bxhcp Sp Ii, Llc 10 percent owner 135 E 57TH STREET, 23RD FLOOR, NEW YORK NY 10022
Bxhcp Sp Iii, Llc 10 percent owner 229 DAWSON ROAD, HILLSDALE NY 12529